Akanda (AKAN) Common Equity (2020 - 2025)
Akanda's (AKAN) quarterly Common Equity came in at -$12.0 million in Q4 2025, down 380.38% year-on-year from $4.3 million in Q4 2024, and down 463.21% quarter-over-quarter from $3.3 million in Q2 2025.
Akanda (AKAN) Common Equity (2020 - 2025) Analysis & Trends
Akanda's Common Equity history runs 6 years deep, the most recent figure standing at -$12.0 million for Q4 2025.
- On a quarterly basis, Common Equity fell 380.38% year-over-year to -$12.0 million in Q4 2025; TTM through Dec 2025 was -$12.0 million, a 380.38% decrease from a year earlier, with the FY2025 full-year figure at -$12.0 million, down 380.38% from the prior year.
- Common Equity slipped to -$12.0 million in Q4 2025 per AKAN's latest filing, from $3.3 million in the prior quarter.
- Across five years, Common Equity topped out at $34.6 million in Q2 2022 and bottomed at -$12.0 million in Q4 2025.
- The 5-year median for Common Equity is $4.3 million (2024), against an average of $8.6 million.
- Across the five-year window, Common Equity soared 1321.94% in 2022 and sank 380.38% in 2025, its largest moves.
- Year by year, Common Equity stood at -$2.2 million in 2021, then surged by 1321.94% to $26.9 million in 2022, then sank by 114.23% to -$3.8 million in 2023, then jumped by 211.69% to $4.3 million in 2024, then sank by 380.38% to -$12.0 million in 2025.
- Per Business Quant, the three latest AKAN Common Equity figures stand at -$12.0 million (Q4 2025), $3.3 million (Q2 2025), and $4.3 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Akanda | 556,353.85 | 556,353.85 | - | -11.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.99 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Dec 31, 2024 | 4.28 Mn |
| Jun 30, 2024 | 4.57 Mn |
| Dec 31, 2023 | -3.83 Mn |
| Jun 30, 2023 | 21.65 Mn |
| Dec 31, 2022 | 26.90 Mn |
| Jun 30, 2022 | 34.64 Mn |
| Dec 31, 2021 | -2.20 Mn |
| Dec 31, 2020 | -5.03 Mn |